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Gene expression analysis is a widely used and powerful method for investigating the transcriptional
behavior of biological systems, for classifying cell states in disease, and for many other purposes.
Recent studies indicate that commonassumptions currently embedded in experimental and analyt-
ical practices can lead to misinterpretation of global gene expression data. We discuss these
assumptions and describe solutions that should minimize erroneous interpretation of gene expres-
sion data from multiple analysis platforms.Global Gene Expression Analysis
Global gene expression analysis provides quantitative informa-
tion about the population of RNA species in cells and tissues.
It is an exceptionally powerful tool of molecular biology that is
used to explore basic biology, diagnose disease, facilitate drug
discovery and development, tailor therapeutics to specific
pathologies and generate databases with information about
living processes. Consequently, expression analysis is among
the most commonly used methods in modern biology; there
are over 750,000 expression data sets in the National Center
for Biotechnology Information Gene Expression Omnibus
(GEO) public database (Edgar et al., 2002).
Global gene expression analysis uses DNA microarrays,
RNA-Seq, and other methods to measure the levels of RNA
species in biological systems (Geiss et al., 2008; Heller,
2002; Lockhart and Winzeler, 2000; Ozsolak and Milos, 2011;
Schena et al., 1998; Wang et al., 2009). DNA microarrays,
which have been most frequently used for expression analysis,
consist of millions of individual oligonucleotide probes fixed
to a solid surface. The oligonucleotide probes typically have
sequences representative of known RNA species and are
generally used to quantitate the relative levels of RNA spe-
cies that hybridize to the probes. Massively parallel sequenc-
ing technologies, developed more recently, provide a mea-
sure of the frequency of RNA species through sequencing of
RNA-derived cDNA populations. Other approaches, such as
digital molecular barcoding, represent a fusion of the hybridi-
zation and counting approaches. For instance, the nCounter
digital quantification platform relies on hybridization of labeled
probes to RNA molecules and single-molecule imaging to
provide a measurement of the frequency of particular RNA
species.476 Cell 151, October 26, 2012 ª2012 Elsevier Inc.Assumptions and Interpretation
Almost all global expression analysis involves isolation of RNA
from two or more cellular sources, introducing similar amounts
of RNA from the sources into the experimental platform and
analyzing the data by using algorithms that normalize the signal
from the samples (Kulkarni, 2011; Mortazavi et al., 2008; Quack-
enbush, 2002; Schulze andDownward, 2001). If the cellular sour-
ces produce equivalent amounts of RNA/cell, and the yields of
RNA and its derivatives are equivalent throughout experimental
manipulation, then normalized expression data should produce
an accurate representation of the relative levels of each gene
product.
We recently found that cells with high levels of c-Myc can
amplify their gene expression program, producing two to three
times more total RNA and generating cells that are larger than
their low-Myc counterparts (Lin et al., 2012; Nie et al., 2012).
This discovery has led us to question the common assumption
that cells produce similar levels of RNA/cell and the general
practice of introducing similar amounts of total RNA into analysis
platforms without including standardized controls that would
reveal transcriptional amplification or repression. As described
below, it is likely that this assumption and practice has led to
erroneous interpretations. We describe here an experimental
approach to genome-wide analysis of RNA expression that is
more likely to produce accurate assessments of changes in
steady-state levels of RNA.
Consider two different models for changes in gene expression
(Figure 1). In the first, RNA levels for a minority of genes are
elevated, but the levels of total RNA in the two cells are similar
(Figure 1A). The absolute levels of most RNA species are there-
fore similar in the two cells, and when the total signal for the RNA
population is normalized by standard algorithms, the resulting
Figure 1. Normalization and Interpretation of Expression Data
(A) Schematic representation of pattern of change in gene expression when levels of total RNA in the two cells are similar. The square box represents
a perturbation such as increased expression of a gene regulator or a change in environment or cell state. Red arrows point to target genes affected by the
perturbation, which are represented as circles. Red shading of circles indicates relative transcriptional increase.
(B) Schematic representation of microarray normalization when the overall levels of mRNA per cell are not changing in two conditions. Relative mRNA levels for
nine different genes (A-I) are indicated along the y axis for condition 1 (black) and condition 2 (orange). The panels, from left to right, depict the actual relationship
between mRNA levels for the two conditions; the effect of median normalization; the calculated fold-changes based on median normalization, with increased
expression represented by red bars above the midline and decreased expression represented by green bars below the midline; and the perceived transcriptional
response of a limited transcriptional increase in gene expression.
(C) Schematic representation of pattern of change in gene expression when levels of total RNA in the two cells is different such as in transcriptional amplification,
where most genes are expressed at higher levels. The square box represents a perturbation such as increased expression of a gene regulator or a change in
environment or cell state. Red arrows point to target genes affected by the perturbation, which are represented as circles. Red shading of circles indicates relative
transcriptional increase.
(D) Schematic representation of microarray normalization when the overall levels of mRNA per cell are increased in one condition compared to another. Relative
mRNA levels for nine different genes (A–I) are indicated along the y axis for condition 1 (black) and condition 2 (orange). The panels, from left to right, depict the
actual relationship between mRNA levels for the two conditions; the effect of median normalization; the calculated fold changes based on median normalization,
with increased expression represented by red bars above themidline and decreased expression represented by green bars below themidline; and the perceived
transcriptional response following transcriptional amplification of gene expression.expression data appropriately indicates an increase in the rela-
tive RNA levels for a set of genes (Figure 1B). In the second
model, the two cells express a similar set of genes, but one
cell produces and accumulates two to three times more RNA/
gene for many of the same genes expressed in the other cell
(Figure 1C), an effect that has been termed transcriptional ampli-
fication (Lin et al., 2012; Nie et al., 2012). In the conventional
approach to expression analysis, similar amounts of RNA from
the two cells are introduced into the assay, thus masking the
fact that one of the cells has two to three times more RNA than
the other (Figure 1D). This potential source of error is typically
overlooked because of the commonly believed, though rarely
stated, assumption that the absolute amount of total mRNA in
each cell is similar across different cell types or experimental
perturbations. Furthermore, the most commonly used analysis
methods are primarily intended to account for technical varia-
tions in signal to noise and assume that the signals for different
samples from different experiments should be scaled to have
the same median or average value or that the distributions of
signal intensities for each experiment within a set should all be
the same (Bolstad et al., 2003; Huber et al., 2002; Irizarry et al.,
2003; Kalocsai and Shams, 2001; Li and Wong, 2001; Reimers,2010; Wu et al., 2004). Normalization of signal from cells that
experience transcriptional amplification can thus have the net
result of equalizing values that are actually different and pro-
ducing the erroneous perception that some genes have elevated
expression, whereas a similar number of genes have reduced
expression.
Experimental Approach
To produce a reliable gene expression analysis protocol that
addresses this experimental and data normalization issue, we
investigated the use of spiked-in standards (Benes and Muck-
enthaler, 2003; Hartemink et al., 2001; Hill et al., 2001; Jiang
et al., 2011;Mortazavi et al., 2008).We implemented an approach
that uses spiked-in RNA standards to allow normalization to cell
number and permit correction for differences in yields during
experimental manipulation (Figure 2A). We performed genome-
wide analysis on P493-6 cells expressing low or high levels of
c-Myc (Pajic et al., 2000; Schuhmacher et al., 1999) in which cells
with high levels of the transcription factor were found to produce
2- to 3-fold higher levels of the same RNA species found in cells
with low levels (Lin et al., 2012). Cell number was determined
by counting cells with C-Chip disposable hemocytometersCell 151, October 26, 2012 ª2012 Elsevier Inc. 477
Figure 2. Spike-In Controls, Normalized to Cell Number, Enable Accurate Interpretation of Transcriptional Changes
(A) Schematic representation ofmicroarray normalizationwhen the total level of mRNAper cell is different as in transcriptional amplification, but spike-in RNAs are
used as standards for normalization. mRNA levels are indicated along the y axis for condition 1 (black) and condition 2 (orange); individual genes are represented
along the x axis. Spike-in standards in the mRNA for condition 1 are represented by black triangles and spike-in standards in the mRNA for condition 2 are
represented by orange triangles (S1–S3). The panels, from left to right, depict the actual relationship between mRNA levels for the two conditions; the effect of
normalization using the spike-in standards; the resulting fold changes from condition 1 and condition 2, where increased expression is represented by red bars
above the midline; and the perceived transcriptional response following transcriptional amplification of gene expression normalized with spike-in RNAs.
(B) Heatmap showing the results of different normalizationmethods on the interpretation of microarray data. The data represent fold change of expression in high-
Myc versus low-Myc cells. Each line represents data for individual probes on the microarray. Red indicates increased expression in high-Myc versus low-Myc
cells. Green indicates decreased expression in high-Myc versus low-Myc cells. Black indicates no change in expression. Left: data using a standard microarray
normalization method (MAS5). Right: the same data, now renormalized by using spike-in standards.
(C) Heatmap showing the results of different normalization methods on the interpretation of RNA-sequencing data. The data represent fold change of expression
in high-Myc versus low-Myc cells. Each line represents data for an individual gene. Red indicates increased expression in high-Myc versus low-Myc cells. Green
indicates decreased expression in high-Myc versus low-Myc cells. Black indicates no change in expression. Left: data using a standard sequencing normalization
(reads per kilobase of exon model per million mapped reads). Right: the same data, now renormalized by using spike-in standards.
(D) Heatmap showing the results of different sample preparation methods on the interpretation of digital quantification data. The data represent fold change of
counts of mRNA molecules in high-Myc versus low-Myc cells. Each line represents data for an individual gene. Red indicates increased expression in high-Myc
versus low-Myc cells. Green indicates decreased expression in high-Myc versus low-Myc cells. Black indicates no change in expression. Left: the results if the
quantification is performed with equal amounts of total RNA for the high-Myc versus low-Myc cells. Right: the results if the quantification is performed with RNA
from equal numbers of high-Myc and low-Myc cells.(Digital Bio) and equivalent numbers of high- and low-Myc cells
were harvested. The DNA content of the two samples was
measured and found to be equivalent. Following total RNA
extraction, spiked-in RNA standards were added in proportion
to the number of cells present in the sample. Samples were
then split andprepared formicroarray, RNA-seq, anddigital anal-
ysis by using NanoString.
DNA-microarrays were first used to compare the high-Myc
versus low-Myc cell RNA populations (Figure 2B; Table S1 avail-
able online). Similar amounts of RNA from the low- and high-Myc
cells were introduced into the Affymetrix DNA microarray assay478 Cell 151, October 26, 2012 ª2012 Elsevier Inc.following the manufacturer’s protocol, which is the most com-
mon approach used in expression analysis. The resulting data
were processed by using standard normalization methods and
by using the spike-in standards for normalization. The results ob-
tained by using standard approaches can be interpreted tomean
that the expression levels of some genes are unchanged,
whereas others increase or decrease (Figure 2B). The interpreta-
tion is quite different when the same data is normalized by using
spike-in standards that reflect cell number: 90% of the genes
show increases in expression in high-Myc cells relative to low-
Myc cells (Figure 2B).
RNA-Seq analysis was then used to compare the high-Myc
versus low-Myc cell RNA populations (Figure 2C; Table S2).
Similar amounts of RNA from the low- and high-Myc cells were
subjected to sequencing. The resulting data were processed
by using standard normalization methods and by using the
spike-in standards for normalization. Again, the results obtained
by using standard approaches suggest that the expression
levels of some genes are unchanged, whereas others increase
or decrease (Figure 2C), yet when the same data are normalized
by using spike-in standards that reflect cell number, there is
an increase in transcript levels for the vast majority of genes
(Figure 2C).
We then used whole-sample, digital gene expression quantifi-
cation (NanoString, Seattle, WA) to compare transcript levels
in the high-Myc and low-Myc cells. In one experiment, equal
amounts of RNA from the high- and low-Myc cells were com-
pared by using this method. The results of this analysis sug-
gest that the expression levels of some genes is unchanged,
whereas others increase or decrease. In a second experiment,
equal numbers of high- and low-Myc cells were used to prepare
RNA, and these total RNA populations were subjected to digital
gene expression quantification. Here, the data indicate there is
an increase in transcript levels for the vast majority of genes in
high- versus low-Myc cells (Figure 2D, Table S3).
In summary, three of the major technologies typically used for
global gene expression analysis—microarray, RNA-sequencing,
and digital quantification—detect a widespread increase in tran-
scripts/cells in cells that experience transcriptional amplification
by c-Myc. Significantly, all three of these major technologies
used for gene expression fail to detect the widespread increase
of transcription when inappropriate normalization methods are
used. Instead, they erroneously suggest the interpretation that
a similar number of genes show increases and decreases in
expression.
Implications
Our results indicate that spike-in controls of the type described
here are a robust, cross-platform method to allow normalization
to cell number and thus enablemore accurate detection of differ-
ential gene expression and changes in gene expression pro-
grams. The clear implication is that the use of spike-in controls
normalized to cell number should become the default standard
for all expression experiments, as opposed to their more limited
use in experiments where gross changes in RNA levels are
already anticipated, as exemplified by transcription shutdown
experiments (Bar-Joseph et al., 2012). When cell counting may
be problematic, as for expression experiments from solid tumors
or tissues, DNA content may be used as a surrogate if ploidy and
DNA replication profiles are also characterized to prevent the
introduction of a DNA content-based artifact.
The discovery of transcriptional amplification and the realiza-
tion that common experimental methods may lead to erroneous
interpretation of gene expression experiments has implications
for much current biological research. How prevalent is misinter-
pretation of genome-wide expression data due to the assump-
tion that cells produce similar levels of total RNA? The answer
is likely related to the prevalence of regulatory mechanisms
that globally amplify or suppress transcription. What are theimplications for classifying cell states in disease? Significant
effort is being devoted to expression profiling cancer cells and
these studies use standard normalization methods (Alizadeh
et al., 2000; Beer et al., 2002; Berger et al., 2010; Bhattacharjee
et al., 2001; Bittner et al., 2000; Golub et al., 1999; Lapointe et al.,
2004; Northcott et al., 2012; Ramaswamy et al., 2001; Ross
et al., 2000; Schmitz et al., 2012; Shipp et al., 2002; Su et al.,
2001; Cancer Genome Atlas, 2012; van ’t Veer et al., 2002;
van de Vijver et al., 2002; Yeoh et al., 2002). Because c-Myc
expression occurs at widely varying levels in various tumor cells,
transcriptional amplification is likely having a profound impact on
cancer cell signatures. Where expression data are being used to
gain insights into cancer cell behavior and regulation, it should
be interpreted with added caution.
Experimental Procedures
Cell Culture
P493-6 cells were kindly provided by Chi Van Dang, University of
Pennsylvania. Cells were propagated in RPMI-1640 supple-
mented with 10% fetal bovine serum and 1% GlutaMAX (Invitro-
gen, 35050-061). The conditional pmyc-tet construct in P493-6
cells was repressed with 0.1 mg/ml tetracycline (Sigma, T7660)
for 72 hr. Cells were then washed three times with RPMI-1640
medium containing 10% tetracycline system approved FBS
(Clontech, 631105) and 1% GlutaMAX and recultured in tetracy-
cline-free culture conditions. All experiments were performed in
the absence of EBNA2 activation. Cell numberswere determined
by manually counting cells with C-Chip disposable hemocytom-
eters (Digital Bio, DHC-N01) prior to lysis and RNA extraction.
RNA Extraction and Synthetic RNA Spike-In
Ten million P493-6 cells were homogenized in 1 ml of TRIzol
Reagent (Life Technologies, 15596-026), purified with the
mirVANA miRNA isolation kit (Ambion, AM1560) following
the manufacturer’s instructions and resuspended in 100 ml
nuclease-free water (Ambion, AM9938). Total RNA was spiked-
in with the External RNA Controls Consortium (ERCC) ExFold
RNA spike-in controls, treated with DNA-free DNase I (Ambion,
AM1906), and analyzed on Agilent 2100 Bioanalyzer for integrity.
The external control spike-ins used in the microarray and RNA-
Seq analysis were obtained from the ERCCExFold RNASpike-In
kit (Ambion, 4456739). The ERCC RNA Spike-In Control Mixes
used here comprise a set of 92 polyadenylated transcripts that
mimic natural eukaryotic mRNAs. The RNAs range in size from
250–2,000 nucleotides in length and span an approximately
106-fold concentration range.
After extracting total RNA from equal numbers of cells, a fixed
amount of diluted ERCC Spike-In Mix #1 was added. The
amount of spike-in added was calibrated to the RNA yield of
the high-Myc cells to ensure the spike-in signal was in the appro-
priate dynamic range (ERCC User Guide, Table 4). For these
experiments, 1ml of a 1:10 dilution of Mix #1 was added to total
RNA extracted from 1 3 106 cells. RNA with the RNA integrity
number (RIN) above 9.8 was used for library generation for
RNA-Seq or hybridized to GeneChip PrimeView Human Gene
Expression Arrays (Affymetrix) by using 10 mg or 100 ng of total
RNA, respectively.
For these experiments, we followed the manufacturer’s
recommendation and added the spike-in controls to total RNACell 151, October 26, 2012 ª2012 Elsevier Inc. 479
following RNA extraction. However, we have found that spike-in
controls can also be added directly to the sample-Trizol homog-
enate prior to RNA purification if desired.
Microarray Sample Preparation and Analysis
For microarray analysis, 100 ng of total RNA containing ERCC
ExFold Mix #1 RNA spike-in controls (see above) was used to
prepare biotinylated aRNA (cRNA) according to the manufac-
turer’s protocol (30 IVT Express Kit, Affymetrix 901228). Gene-
Chip arrays (Primeview, Affymetrix 901837) were hybridized
and scanned according to standard Affymetrix protocols. All
samples were processed in technical duplicate. Imageswere ex-
tracted with Affymetrix GeneChip Command Console (AGCC)
and analyzed by using GeneChip Expression Console. A Prime-
view Chip Definition File that included probe information for the
ERCC controls, provided by Affymetrix, was used to generate
CEL files. We processed the CEL files by using standard tools
available within the affy package in R. The CEL files were pro-
cessed with the expresso command to convert the raw probe
intensities to probe set expression values. The parameters of
the expresso command were set to generate Affymetrix MAS5-
normalized probe set values. We used a loess regression to
renormalize these MAS5 normalized probe set values by using
only the spike-in probe sets to fit the loess. The affy package
provides a function, loess.normalize, which will perform loess
regression on a matrix of values (defined by using the parameter
mat) and allows for the user to specify which subset of data to use
when fitting the loess (definedby using the parameter subset, see
the affypackagedocumentation for further details). For this appli-
cation, the parameters mat and subset were set as the MAS5-
normalized values and the row indices of the ERCCcontrol probe
sets, respectively. The default settings for all other parameters
were used. The result of this was a matrix of expression values
normalized to the control ERCC probes. The probe set values
from the duplicates were averaged together and the log2 fold
change from the low-Myc to the high-Myc samples are shown.
RNA-Seq Sample Preparation and Analysis
Using 10 mg of total RNA containing ERCC ExFold Mix #1 RNA
spike-in controls (see above), we prepared sequencing libraries
according to the following protocol. Polyadenylated RNA was
purified by two rounds of selection with Dynabeads mRNA
Purification Kit for mRNA Purification from total RNA (Life Tech-
nologies, 610-06) following the manufacturer instructions. This
resulting RNA was then further processed for RNA-Seq assays.
Briefly, polyadenylated RNA was fragmented with divalent
cations under elevated temperature. First strand cDNA synthesis
was performed with random hexamers and Superscript III
reverse transcriptase (Life Technologies, 18080-051). Second
strand cDNA synthesis was performed by using RNase H and
DNA Polymerase I. In the second-strand synthesis reaction,
dTTP was replaced with dUTP. After cDNA synthesis, the
double-stranded products were end repaired, a single ‘‘A’’
base was added, and Illumina PE adaptors were ligated onto
the cDNA products. The ligation products with an average size
of 300 bp were purified by using agarose gel electrophoresis.
Following gel purification, the strand of cDNA containing dUTP
was selectively destroyed during incubation of purified double-
stranded DNA with HK-UNG (Epicenter, HU59100). The adaptor
ligated single-stranded cDNA was then amplified with 15 cycles480 Cell 151, October 26, 2012 ª2012 Elsevier Inc.of PCR and PCR products were purified by using gel electropho-
resis. These RNA-Seq libraries were subsequently sequenced
on Illumina HiSeq 2000. Sequences were aligned by using Bow-
tie (version 0.12.2) to build version NCBI36/HG18 of the human
genome where the sequences of the ERCC synthetic spike-in
RNAs (http://tools.invitrogen.com/downloads/ERCC92.fa) had
been added. The RPKM (reads per kilobase of exon per million)
was then computed for each gene and synthetic spike-in RNA.
We used a loess regression to renormalize the RPKM values
by using only the spike-in values to fit the loess. The affy package
in R provides a function, loess.normalize, which will perform
loess regression on a matrix of values (defined by using the
parameter mat) and allows for the user to specify which subset
of data to use when fitting the loess (defined by using the param-
eter subset, see the affy package documentation for further
details). For this application the parameters mat and subset
were set as a matrix of all RPKM values and the row indices of
the ERCC spike-ins, respectively. The default settings for all
other parameters were used. The result of this was a matrix of
RPKM values normalized to the control ERCC spike-ins. Eigh-
teen thousand five hundred and thirty-six genes with a RPKM
value of 1.0 or greater in the low-Myc sample were selected,
and the log2 fold ratio between the low-Myc and high-Myc
samples were calculated and shown as a heatmap.
NanoString nCounter Gene Expression Assay Sample
Preparation and Analysis
For digital gene expression using NanoString nCounter Gene
Expression CodeSets, 1 3 106 cells were collected and lysed
directly either in 100 ml RLT buffer (QIAGEN, 74104) to yield
a concentration of 10,000 cells per ml or in 500 ml lysis buffer
with the mirVANA miRNA isolation kit (Ambion, AM1560).
Samples were processed according to the cell lysate protocol
(nCounter Gene Expression Protocol, NanoString) or the total
RNA extraction protocol (Ambion). Four ml of cell lysate (for
cell-count normalization) or 100 ng of total RNA (for total RNA
normalization) was subsequently incubated overnight at 65C
in nCounter Reporter CodeSet, Capture ProbeSet, and hybrid-
ization buffer. Following hybridization, samples were immedi-
ately processed with the nCounter PrepStation and subse-
quently analyzed on an nCounter Digital Analyzer. All samples
were processed in biological duplicate.
We used two custom nCounter Reporter CodeSets en-
compassing 429 genes. These codesets encompassed sets of
known cancer related genes (CodeSets CS-1 and CS-2)
(Delmore et al., 2011). For each NanoString data set, we used
a piecewise linear interpolation of control RNAs (added after
hybridization as part of the nCounter PrepStation protocol) to
their known concentrations to normalize each data set. Two
hundred and sixty-six genes showing expression with a normal-
ized value of 1.0 or greater in both the low-Myc Total-RNA and
low-Myc Cell-Count samples were selected, and the log2 fold
ratio between the low-Myc and high-Myc samples were calcu-
lated and shown as a heatmap.ACCESSION NUMBERS
Raw and normalized microarray and RNA-Seq data can be found online asso-
ciated with the GEO Accession ID GSE40784.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three tables and can be found with this
article online at http://dx.doi.org/10.1016/j.cell.2012.10.012.
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